A nonvirulent tumor-targeting bacterial strain bioengineered to release multiple Toll-like receptor (TLR) ligands was shown to suppress tumor growth and prolong survival in mouse tumor models in a Korean study, suggesting it could be a new cancer immunotherapy in humans.